Oral tapentadol for cancer pain

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 7, 2015, Pages

  Wiffen, Philip J ^a   Derry, Sheena ^a   Naessens, Katrien ^b   Bell, Rae F ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; OXYCODONE; PLACEBO; TAPENTADOL; MU OPIATE RECEPTOR; PHENOL DERIVATIVE;

ADULT; AGED; ANALGESIA; ANOREXIA; CANCER PAIN; CONSTIPATION; DECREASED APPETITE; DELIRIUM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN INTENSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; STOMATITIS; SYSTEMATIC REVIEW; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; COMPLICATION; META ANALYSIS; NEOPLASM; PAIN;

ADULT; HUMANS; NEOPLASMS; PAIN; PHENOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, MU;

EID: 84960505195     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011460.pub2     Document Type: Review

References (26)

1. Imanaka K, Tominaga Y, Etropolski M, Van Hove I, Ohsaka M, Wanibe M, et al. Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion 2014;30(9):1909-10. [DOI: 10.1185/03007995.2014.919909]3242901
2. Imanaka K, Tominaga Y, Etropolski M, van Hove I, Ohsaka M, Wanibe M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion 2013;29(10):1399-409. [DOI: 10.1185/03007995.2013.831816]3242902
3. Janssen Research and Development, LLC. A safety and efficacy study of JNS024 extended release (ER) in Japanese and Korean patients with chronic malignant tumor-related cancer pain. www.clinicaltrials.gov/ct2/show/NCT01165281 (accessed 14 January 2015) 2013. [CTG: NCT01165281]3242903
4. Imanaka K, Tominaga Y, Etropolski M, Ohashi H, Hirose K, Matsumura T. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical Drug Investigation 2014;34(7):501-11. [DOI: 10.1007/s40261-014-0204-3; Clinicaltrials.gove identifier: NCT01309386]3242905
5. Janssen Pharmaceutical KK. A safety and efficacy study of oral tapentadol extended-release in Japanese participants. www.clinicaltrials.gov/ct2/show/NCT01309386 (accessed 14 January 2015) 2013. [CTG: NCT01309386]3242906
6. Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015) 2014. [CTG: NCT00472303]3242908
7. Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician 2014;17(4):329-43. [PUBMED: 25054392]3242909
8. Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015) 2010. [CTG: NCT00505414]3242911
9. Cancer Research UK. Cancer incidence for all cancers combined. info.cancerresearchuk.org/cancerstats/incidence/all-cancers-combined/(accessed 7 September 2015).
10. Cleary JF. The pharmacologic management of cancer pain. Journal of Palliative Medicine 2007;10(6):1369-94. [DOI: 10.1089/jpm.2007.9842]
11. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310(6977):452-4.
12. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
13. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
14. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107(2):224-33.
15. McQuay H, Moore R. An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-263048-2]
16. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
17. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: Moore RA, Kalso E, McQuay HJ editor(s). Systematic Reviews in Pain Research: Methodology Refined. 1st Edition. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0931092695]
18. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]
19. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
20. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editor(s). Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: BMJ Books, 1995:50-63.
21. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
22. Santos J, Alarcão J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD009923.pub2]
23. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997;315(7109):635-40.
24. Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 2014;29:319-29. [DOI: 10.1007/s40263-014-0151-9]
25. Davis H. Tapentadol prolonged release. UKMI New Medicine Profile 2011, issue 3:1-5.
26. Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2]